Home / Recalls / Exela Pharma Sciences LLC / D-0023-2023

D-0023-2023 Class I Terminated

Recalled by Exela Pharma Sciences LLC — Lenoir, NC

FDA drug recall D-0023-2023 was initiated by Exela Pharma Sciences LLC on Oct 4, 2022 and is designated Class I. Reason for recall: Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration The recall status is terminated (terminated Oct 10, 2025). Affected quantity: 148,920.

Recall Details

Product Type: Drugs
Report Date: Nov 2, 2022
Initiation Date: Oct 4, 2022
Termination Date: Oct 10, 2025
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 148,920

Product Description

8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) 50 mL Single Dose Vials, packaged in cartons of 20 vials, Rx Only, Mfd for: Civica, Inc. Lehi, Utah 84043, Mfd by: Exela Pharma Sciences, LLC, Lenoir, NC 28645, Carton NDC 72572-740-20, vial NDC 72572-740-1.

Reason for Recall

Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration

Distribution Pattern

Nationwide within the United States

Code Information

Lot #: P0001497 Exp. 12/2023; P0001600 Exp. 02/2024; P0001663 Exp. 03/2024

Source

Dataset: openFDA drug recall enforcement reports
FDA record: This recall in openFDA (JSON)
Enforcement Report: Search FDA's Enforcement Report for D-0023-2023
openFDA file date: Nov 3, 2026
Loaded by RegDataLab: Nov 4, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Other recalls by Exela Pharma Sciences LLC

D-0620-2025 Class II — 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), For… (Jul 30, 2025)
D-0303-2025 Class II — 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL (1 mEq/mL), 25 x 50 mL… (Mar 7, 2025)
D-0117-2024 Class I — Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL (1mg/mL), 100 mL… (Oct 18, 2023)
D-0118-2024 Class I — ELCYS (cysteine hydrochloride injection), USP, 500 mg/10mL (50 mg/mL), 10x10 mL… (Oct 18, 2023)
D-0116-2024 Class I — 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL (1mEq/mL), a) 20x50 mL… (Oct 18, 2023)
D-0079-2023 Class I — 8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) 50 mL Single Dose… (Nov 28, 2022)
D-0080-2023 Class I — 8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) 50 mL Single Dose… (Nov 28, 2022)
D-0022-2023 Class I — 8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL) 50 mL Single Dose… (Oct 4, 2022)
D-0369-2022 Class II — 8.4% Sodium Bicarbonate Injection, USP 50 mEq/50 mL (1 mEq/mL), 50 mL vials, Rx… (Jan 11, 2022)
D-1585-2020 Class III — Potassium Acetate Injection, USP 40 mEq/20 mL (2 mEq/mL) Single Dose Vials, Rx… (May 5, 2020)